PROGEN’s Peptide Mapping Antibody Validation Initiative Earns CiteAb Commendation


Scientists need reliable antibodies that generate reproducible data. German manufacturer PROGEN has launched a truly novel validation program that utilizes the peptide mapping technology of

its collaborator PEPperPRINT to evaluate the performance of its antibodies. The peptide microarray platform enables the analysis of peptides covering up to 20 proteins on the same array with a

single amino acid resolution and generates dependable data on epitope binding, selectivity and specificity of the antibody in question.

This innovative validation initiative has been highly commended by CiteAb in the 2018 awards and is yet another module in PROGEN’s multiple actions to provide premium antibodies. The company plans to implement the independent peptide mapping validation for the majority of its antibodies to offer additional value to the research community.